XML 76 R66.htm IDEA: XBRL DOCUMENT v3.22.2.2
Segment Information - Net Sales and Operating Income (Loss) by each Reportable Segment (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Segment Reporting Information [Line Items]        
Net sales $ 67,689 $ 63,074 $ 193,466 $ 191,206
Cost of sales 12,188 10,129 33,947 32,530
Selling, general and administrative expense 53,475 46,289 158,838 145,291
Research and development expense 5,953 4,368 17,429 12,770
Amortization of intangible assets 175 193 519 647
Investigation, restatement and related expense 3,001 3,170 8,771 8,304
Operating loss (7,103) (1,075) (26,038) (8,336)
Supplemental information        
Depreciation expense 831 923 2,549 3,390
Share-based compensation 2,372 3,811 10,798 11,115
Corporate & Other        
Segment Reporting Information [Line Items]        
Net sales 816 860 2,169 2,221
Cost of sales 1,029 1,189 2,821 3,232
Selling, general and administrative expense 17,944 12,900 50,582 46,772
Research and development expense 0 0 0 0
Amortization of intangible assets 175 193 519 647
Investigation, restatement and related expense
Operating loss
Supplemental information        
Depreciation expense 344 378 1,065 2,005
Share-based compensation 80 2,054 4,279 6,141
Wound & Surgical | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 66,873 62,138 191,297 172,401
Cost of sales 11,159 8,924 31,126 25,646
Selling, general and administrative expense 35,531 32,104 108,256 87,392
Research and development expense 1,680 1,423 6,068 4,080
Amortization of intangible assets   0 0 0
Segment contribution 18,503 19,687 45,847 55,283
Investigation, restatement and related expense  
Operating loss
Supplemental information        
Depreciation expense 451 511 1,364 1,172
Share-based compensation 1,945 1,435 5,609 3,827
Regenerative Medicine | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 0 76 0 16,584
Cost of sales 0 16 0 3,652
Selling, general and administrative expense 0 1,285 0 11,127
Research and development expense 4,273 2,945 11,361 8,690
Amortization of intangible assets   0 0 0
Segment contribution (4,273) (4,170) (11,361) (6,885)
Investigation, restatement and related expense  
Operating loss
Supplemental information        
Depreciation expense 36 34 120 213
Share-based compensation $ 347 $ 322 $ 910 $ 1,147